VERTEX PHARMACEUTICALS INC / MA Revenue
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Revenue of $3.33 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $3.33B, a 12.45% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $2.99B, a 7.82% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $3.19B, a 9.55% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $3.08B, a 10.99% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA revenue from contract with customer, excluding assessed tax for fiscal 2025 was $12.00B, a 8.90% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA revenue from contract with customer, excluding assessed tax for fiscal 2024 was $11.02B, a 11.66% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA revenue from contract with customer, excluding assessed tax for fiscal 2023 was $9.87B, a 10.51% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA revenue from contract with customer, excluding assessed tax for fiscal 2022 was $8.93B, a 17.91% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.33B 10-Q · filed 2026-08-04 | $6.32B 10-Q · filed 2026-08-04 | $9.51B derived: sum of 3 quarters · filed 2026-08-04 | $12.59B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $2.99B 10-Q · filed 2026-05-05 | $6.18B derived: sum of 2 quarters · filed 2026-05-05 | $9.25B derived: sum of 3 quarters · filed 2026-05-05 | $12.22B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $3.19B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $6.27B derived: sum of 2 quarters · filed 2026-02-13 | $9.23B derived: sum of 3 quarters · filed 2026-08-04 | $12.00B 10-K · filed 2026-02-13 | ||||
| 2025-09-30 | $3.08B 10-Q · filed 2025-11-04 | $6.04B derived: sum of 2 quarters · filed 2026-08-04 | $8.81B 10-Q · filed 2025-11-04 | $11.72B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $2.96B 10-Q · filed 2026-08-04 | $5.73B 10-Q · filed 2026-08-04 | $8.65B derived: sum of 3 quarters · filed 2026-08-04 | $11.42B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $2.77B 10-Q · filed 2026-05-05 | $5.68B derived: sum of 2 quarters · filed 2026-05-05 | $8.45B derived: sum of 3 quarters · filed 2026-05-05 | $11.10B derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $2.91B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $5.68B derived: sum of 2 quarters · filed 2026-02-13 | $8.33B derived: sum of 3 quarters · filed 2026-02-13 | $11.02B 10-K · filed 2026-02-13 | ||||
| 2024-09-30 | $2.77B 10-Q · filed 2025-11-04 | $5.42B derived: sum of 2 quarters · filed 2025-11-04 | $8.11B 10-Q · filed 2025-11-04 | $10.63B derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-06-30 | $2.65B 10-Q · filed 2025-08-05 | $5.34B 10-Q · filed 2025-08-05 | $7.85B derived: sum of 3 quarters · filed 2026-02-13 | $10.34B derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-03-31 | $2.69B 10-Q · filed 2025-05-06 | $5.21B derived: sum of 2 quarters · filed 2026-02-13 | $7.69B derived: sum of 3 quarters · filed 2026-02-13 | $10.19B derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2023-12-31 | $2.52B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $5.00B derived: sum of 2 quarters · filed 2026-02-13 | $7.49B derived: sum of 3 quarters · filed 2026-02-13 | $9.87B 10-K · filed 2026-02-13 | ||||
| 2023-09-30 | $2.48B 10-Q · filed 2024-11-05 | $4.98B derived: sum of 2 quarters · filed 2024-11-05 | $7.35B 10-Q · filed 2024-11-05 | $9.65B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $2.49B 10-Q · filed 2024-08-02 | $4.87B 10-Q · filed 2024-08-02 | $7.17B derived: sum of 3 quarters · filed 2025-02-13 | $9.51B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $2.37B 10-Q · filed 2024-05-07 | $4.68B derived: sum of 2 quarters · filed 2025-02-13 | $7.01B derived: sum of 3 quarters · filed 2025-02-13 | $9.21B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $2.30B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $4.64B derived: sum of 2 quarters · filed 2025-02-13 | $6.83B derived: sum of 3 quarters · filed 2025-02-13 | $8.93B 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $2.33B 10-Q · filed 2023-11-07 | $4.53B derived: sum of 2 quarters · filed 2023-11-07 | $6.63B 10-Q · filed 2023-11-07 | $8.70B derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $2.20B 10-Q · filed 2023-08-02 | $4.29B 10-Q · filed 2023-08-02 | $6.37B derived: sum of 3 quarters · filed 2024-02-15 | $8.35B derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $2.10B 10-Q · filed 2023-05-02 | $4.17B derived: sum of 2 quarters · filed 2024-02-15 | $6.15B derived: sum of 3 quarters · filed 2024-02-15 | $7.95B derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $2.07B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $4.06B derived: sum of 2 quarters · filed 2024-02-15 | $5.85B derived: sum of 3 quarters · filed 2024-02-15 | $7.57B 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $1.98B 10-Q · filed 2022-10-28 | $1.98B 10-Q · filed 2021-11-03 | $3.78B derived: sum of 2 quarters · filed 2022-10-28 | $5.50B 10-Q · filed 2022-10-28 | $5.50B 10-Q · filed 2021-11-03 | $7.13B derived: sum of 4 quarters · filed 2022-10-28 | ||
| 2021-06-30 | $1.79B 10-Q · filed 2022-08-05 | $1.79B 10-Q · filed 2021-07-30 | $3.52B 10-Q · filed 2022-08-05 | $3.52B 10-Q · filed 2021-07-30 | $5.15B derived: sum of 3 quarters · filed 2022-08-05 | $6.68B derived: sum of 4 quarters · filed 2022-08-05 | ||
| 2021-03-31 | $1.72B 10-Q · filed 2022-05-06 | $1.72B 10-Q · filed 2021-04-30 | $3.35B derived: sum of 2 quarters · filed 2022-05-06 | $4.89B derived: sum of 3 quarters · filed 2022-05-06 | $6.41B derived: sum of 4 quarters · filed 2022-05-06 | |||
| 2020-12-31 | $1.63B 10-K · filed 2021-02-11 | $3.17B derived: sum of 2 quarters · filed 2021-11-03 | $4.69B derived: sum of 3 quarters · filed 2021-11-03 | $6.21B 10-K · filed 2023-02-10 | $6.21B 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $1.54B 10-Q · filed 2021-11-03 | $3.06B derived: sum of 2 quarters · filed 2021-11-03 | $4.58B 10-Q · filed 2021-11-03 | $5.99B derived: sum of 4 quarters · filed 2021-11-03 | ||||
| 2020-06-30 | $1.52B 10-Q · filed 2021-07-30 | $3.04B 10-Q · filed 2021-07-30 | $4.45B derived: sum of 3 quarters · filed 2021-07-30 | $5.40B derived: sum of 4 quarters · filed 2021-07-30 | ||||
| 2020-03-31 | $1.52B 10-Q · filed 2021-04-30 | $2.93B derived: sum of 2 quarters · filed 2021-04-30 | $3.88B derived: sum of 3 quarters · filed 2021-04-30 | $4.82B derived: sum of 4 quarters · filed 2021-04-30 | ||||
| 2019-12-31 | $1.41B 10-K · filed 2021-02-11 | $2.36B derived: sum of 2 quarters · filed 2021-02-11 | $3.30B derived: sum of 3 quarters · filed 2021-02-11 | $4.16B 10-K · filed 2022-02-09 | $4.16B 10-K · filed 2020-02-13 | |||
| 2019-09-30 | $949.83M 10-K · filed 2021-02-11 | $1.89B derived: sum of 2 quarters · filed 2021-02-11 | $2.75B 10-Q · filed 2020-10-30 | $3.62B derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $941.29M 10-K · filed 2021-02-11 | $1.80B 10-Q · filed 2020-07-31 | $2.67B derived: sum of 3 quarters · filed 2021-02-11 | $3.45B derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $858.43M 10-K · filed 2021-02-11 | $1.73B derived: sum of 2 quarters · filed 2021-02-11 | $2.51B derived: sum of 3 quarters · filed 2021-02-11 | $3.27B derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | $870.11M 10-K · filed 2020-02-13 | $1.65B derived: sum of 2 quarters · filed 2020-02-13 | $2.41B derived: sum of 3 quarters · filed 2020-02-13 | $3.05B 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | $784.53M 10-K · filed 2020-02-13 | $1.54B derived: sum of 2 quarters · filed 2020-02-13 | $2.18B 10-Q · filed 2019-10-31 | $2.83B derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-06-30 | $752.16M 10-K · filed 2020-02-13 | $1.39B 10-Q · filed 2019-08-01 | $2.04B derived: sum of 3 quarters · filed 2020-02-13 | $2.62B derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-03-31 | $640.80M 10-K · filed 2020-02-13 | $1.29B derived: sum of 2 quarters · filed 2020-02-13 | $1.87B derived: sum of 3 quarters · filed 2020-02-13 | $2.41B derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2017-12-31 | $651.63M 10-K · filed 2019-02-13 | $1.23B derived: sum of 2 quarters · filed 2019-02-13 | $1.77B derived: sum of 3 quarters · filed 2019-02-13 | $2.49B 10-K · filed 2020-02-13 | ||||
| 2017-09-30 | $578.16M 10-K · filed 2019-02-13 | $1.12B derived: sum of 2 quarters · filed 2019-02-13 | $1.84B 10-Q · filed 2018-10-25 | |||||
| 2017-06-30 | $544.13M 10-K · filed 2019-02-13 | $1.26B 10-Q · filed 2018-07-26 | ||||||
| 2017-03-31 | $714.72M 10-K · filed 2019-02-13 | |||||||
| 2016-12-31 | $1.70B 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |